Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison

Daratumumab is a human CD38‐directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or who are double refractory to...

Descripción completa

Detalles Bibliográficos
Autores principales: Usmani, Saad Z., Diels, Joris, Ito, Tetsuro, Mehra, Maneesha, Khan, Imran, Lam, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
E‐only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518219/
https://www.ncbi.nlm.nih.gov/pubmed/28474745
http://dx.doi.org/10.1002/ajh.24781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518219/
https://www.ncbi.nlm.nih.gov/pubmed/28474745
http://dx.doi.org/10.1002/ajh.24781

Ejemplares similares